Abstract
Summary
Gene therapy is an experimental technique that uses genes to treat or prevent disease. In the future, this technique may allow doctors to treat a disorder by inserting a gene into a patient's cells instead of using drugs or surgery.
LPI (LP Information)' newest research report, the “Gene Therapy on Neurological Diseases Industry Forecast” looks at past sales and reviews total world Gene Therapy on Neurological Diseases sales in 2022, providing a comprehensive analysis by region and market sector of projected Gene Therapy on Neurological Diseases sales for 2023 through 2029. With Gene Therapy on Neurological Diseases sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Gene Therapy on Neurological Diseases industry.
This Insight Report provides a comprehensive analysis of the global Gene Therapy on Neurological Diseases landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Gene Therapy on Neurological Diseases portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Gene Therapy on Neurological Diseases market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Gene Therapy on Neurological Diseases and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Gene Therapy on Neurological Diseases.
The global Gene Therapy on Neurological Diseases market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Gene Therapy on Neurological Diseases is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Gene Therapy on Neurological Diseases is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Gene Therapy on Neurological Diseases is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Gene Therapy on Neurological Diseases players cover Biogen, Novartis and Sarepta Therapeutics, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Gene Therapy on Neurological Diseases market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Viral Gene Therapy
Non-viral Gene Therapy
Segmentation by application
Hospital
Clinic
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Biogen
Novartis
Sarepta Therapeutics
LPI (LP Information)' newest research report, the “Gene Therapy on Neurological Diseases Industry Forecast” looks at past sales and reviews total world Gene Therapy on Neurological Diseases sales in 2022, providing a comprehensive analysis by region and market sector of projected Gene Therapy on Neurological Diseases sales for 2023 through 2029. With Gene Therapy on Neurological Diseases sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Gene Therapy on Neurological Diseases industry.
This Insight Report provides a comprehensive analysis of the global Gene Therapy on Neurological Diseases landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Gene Therapy on Neurological Diseases portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Gene Therapy on Neurological Diseases market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Gene Therapy on Neurological Diseases and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Gene Therapy on Neurological Diseases.
The global Gene Therapy on Neurological Diseases market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Gene Therapy on Neurological Diseases is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Gene Therapy on Neurological Diseases is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Gene Therapy on Neurological Diseases is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Gene Therapy on Neurological Diseases players cover Biogen, Novartis and Sarepta Therapeutics, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Gene Therapy on Neurological Diseases market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Viral Gene Therapy
Non-viral Gene Therapy
Segmentation by application
Hospital
Clinic
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Biogen
Novartis
Sarepta Therapeutics
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Gene Therapy on Neurological Diseases Market Size 2018-2029
2.1.2 Gene Therapy on Neurological Diseases Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Gene Therapy on Neurological Diseases Segment by Type
2.2.1 Viral Gene Therapy
2.2.2 Non-viral Gene Therapy
2.3 Gene Therapy on Neurological Diseases Market Size by Type
2.3.1 Gene Therapy on Neurological Diseases Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Gene Therapy on Neurological Diseases Market Size Market Share by Type (2018-2023)
2.4 Gene Therapy on Neurological Diseases Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Other
2.5 Gene Therapy on Neurological Diseases Market Size by Application
2.5.1 Gene Therapy on Neurological Diseases Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Gene Therapy on Neurological Diseases Market Size Market Share by Application (2018-2023)
3 Gene Therapy on Neurological Diseases Market Size by Player
3.1 Gene Therapy on Neurological Diseases Market Size Market Share by Players
3.1.1 Global Gene Therapy on Neurological Diseases Revenue by Players (2018-2023)
3.1.2 Global Gene Therapy on Neurological Diseases Revenue Market Share by Players (2018-2023)
3.2 Global Gene Therapy on Neurological Diseases Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Gene Therapy on Neurological Diseases by Regions
4.1 Gene Therapy on Neurological Diseases Market Size by Regions (2018-2023)
4.2 Americas Gene Therapy on Neurological Diseases Market Size Growth (2018-2023)
4.3 APAC Gene Therapy on Neurological Diseases Market Size Growth (2018-2023)
4.4 Europe Gene Therapy on Neurological Diseases Market Size Growth (2018-2023)
4.5 Middle East & Africa Gene Therapy on Neurological Diseases Market Size Growth (2018-2023)
5 Americas
5.1 Americas Gene Therapy on Neurological Diseases Market Size by Country (2018-2023)
5.2 Americas Gene Therapy on Neurological Diseases Market Size by Type (2018-2023)
5.3 Americas Gene Therapy on Neurological Diseases Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Gene Therapy on Neurological Diseases Market Size by Region (2018-2023)
6.2 APAC Gene Therapy on Neurological Diseases Market Size by Type (2018-2023)
6.3 APAC Gene Therapy on Neurological Diseases Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Gene Therapy on Neurological Diseases by Country (2018-2023)
7.2 Europe Gene Therapy on Neurological Diseases Market Size by Type (2018-2023)
7.3 Europe Gene Therapy on Neurological Diseases Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Gene Therapy on Neurological Diseases by Region (2018-2023)
8.2 Middle East & Africa Gene Therapy on Neurological Diseases Market Size by Type (2018-2023)
8.3 Middle East & Africa Gene Therapy on Neurological Diseases Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Gene Therapy on Neurological Diseases Market Forecast
10.1 Global Gene Therapy on Neurological Diseases Forecast by Regions (2024-2029)
10.1.1 Global Gene Therapy on Neurological Diseases Forecast by Regions (2024-2029)
10.1.2 Americas Gene Therapy on Neurological Diseases Forecast
10.1.3 APAC Gene Therapy on Neurological Diseases Forecast
10.1.4 Europe Gene Therapy on Neurological Diseases Forecast
10.1.5 Middle East & Africa Gene Therapy on Neurological Diseases Forecast
10.2 Americas Gene Therapy on Neurological Diseases Forecast by Country (2024-2029)
10.2.1 United States Gene Therapy on Neurological Diseases Market Forecast
10.2.2 Canada Gene Therapy on Neurological Diseases Market Forecast
10.2.3 Mexico Gene Therapy on Neurological Diseases Market Forecast
10.2.4 Brazil Gene Therapy on Neurological Diseases Market Forecast
10.3 APAC Gene Therapy on Neurological Diseases Forecast by Region (2024-2029)
10.3.1 China Gene Therapy on Neurological Diseases Market Forecast
10.3.2 Japan Gene Therapy on Neurological Diseases Market Forecast
10.3.3 Korea Gene Therapy on Neurological Diseases Market Forecast
10.3.4 Southeast Asia Gene Therapy on Neurological Diseases Market Forecast
10.3.5 India Gene Therapy on Neurological Diseases Market Forecast
10.3.6 Australia Gene Therapy on Neurological Diseases Market Forecast
10.4 Europe Gene Therapy on Neurological Diseases Forecast by Country (2024-2029)
10.4.1 Germany Gene Therapy on Neurological Diseases Market Forecast
10.4.2 France Gene Therapy on Neurological Diseases Market Forecast
10.4.3 UK Gene Therapy on Neurological Diseases Market Forecast
10.4.4 Italy Gene Therapy on Neurological Diseases Market Forecast
10.4.5 Russia Gene Therapy on Neurological Diseases Market Forecast
10.5 Middle East & Africa Gene Therapy on Neurological Diseases Forecast by Region (2024-2029)
10.5.1 Egypt Gene Therapy on Neurological Diseases Market Forecast
10.5.2 South Africa Gene Therapy on Neurological Diseases Market Forecast
10.5.3 Israel Gene Therapy on Neurological Diseases Market Forecast
10.5.4 Turkey Gene Therapy on Neurological Diseases Market Forecast
10.5.5 GCC Countries Gene Therapy on Neurological Diseases Market Forecast
10.6 Global Gene Therapy on Neurological Diseases Forecast by Type (2024-2029)
10.7 Global Gene Therapy on Neurological Diseases Forecast by Application (2024-2029)
11 Key Players Analysis
11.1 Biogen
11.1.1 Biogen Company Information
11.1.2 Biogen Gene Therapy on Neurological Diseases Product Offered
11.1.3 Biogen Gene Therapy on Neurological Diseases Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Biogen Main Business Overview
11.1.5 Biogen Latest Developments
11.2 Novartis
11.2.1 Novartis Company Information
11.2.2 Novartis Gene Therapy on Neurological Diseases Product Offered
11.2.3 Novartis Gene Therapy on Neurological Diseases Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Novartis Main Business Overview
11.2.5 Novartis Latest Developments
11.3 Sarepta Therapeutics
11.3.1 Sarepta Therapeutics Company Information
11.3.2 Sarepta Therapeutics Gene Therapy on Neurological Diseases Product Offered
11.3.3 Sarepta Therapeutics Gene Therapy on Neurological Diseases Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Sarepta Therapeutics Main Business Overview
11.3.5 Sarepta Therapeutics Latest Developments
12 Research Findings and Conclusion